By using this website, you consent to our use of cookies. For more information on cookies see our privacy policy page.

Text Size: a a
HomeA-Z IndexSubscribe/RSS Contact Us Twitter logo small white bird


Funded Projects

Contact Us

Research Call

DAFM Reference


DAFM Award

DAFM National Call 2010 10RDTMFRC701 Teagasc (UCC, UL) €300,000

Project Title:

Protection of bioactive peptides using novel encapsulation technologies

Project Coordinator:

Dr Mary Rea

Project Abstract

Even though antimicrobial peptides have significant potential for the positive alteration of gut flora, a significant bottleneck is the bioavailability of the peptides in the gut. We have shown that bacteriocins such as lacticin while highly active against a range of pathogens in vitro are inactivated during gastric transit when pigs were used as model for the human GIT (Gardiner et al 2007). Therefore the objective of this project is to provide proof of concept that encapsulation of bacteriocins and bioactive peptides such as ACE inhibitory peptides or peptides derived from enzymatic hydrolysis of dairy substrates will provide protection of biological activity when orally ingested and therefore can be delivered to targeted sites in the GIT tract. Two differing approaches to encapsulation of the peptides will be employed. It has been previously shown in vivo that, using whey protein micro-beads as delivery systems, probiotics were protected during passage through the stomach but controlled release occurred in the porcine intestine (Doherty, et al PhD thesis 2011). The first approach will thus use a 'wet based' technology (gel-beads) to entrap the peptide while the second approach will exclusively use advanced drying technology to generated protected forms of the peptides. The efficacy of both technologies will then be determined in vitro, and ex vivo using simulated models of t he GIT. The efficacy of encapsulation will then be tested in vivo using the mouse as a model. In addition to the outlined encapsulation procedures, a further technological approach will be investigated whereby pre-treatment of dairy protein substrate may alter the bioavailability of the resulting hydrolysates. A model dual cell culture-based approach involving intestinal epithelial cells will be employed to study the bioavailability/transport of selected peptides/hydrolysates across the gut mucosa.

Final Report:

Final Report - 10RDTMFRC701 (pdf 325Kb)